Pfizer has stopped developing a once-daily pill to treat obesity after a person in a clinical trial showed signs of a possible liver injury. The company said the injury went away after the person stopped taking the drug, called danuglipron, The Associated Press reported. The pill was in early testing to help determine the best… read on > read on >







